Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - What's Next?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s share price gapped up prior to trading on Friday . The stock had previously closed at $36.16, but opened at $37.28. Supernus Pharmaceuticals shares last traded at $37.09, with a volume of 42,602 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SUPN shares. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.0 %

The stock's fifty day moving average price is $35.30 and its 200-day moving average price is $31.91. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of 33.80 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.29) EPS. Analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insiders Place Their Bets

In other news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares of the company's stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 in the last 90 days. 9.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its holdings in shares of Supernus Pharmaceuticals by 377.3% during the 2nd quarter. SG Americas Securities LLC now owns 18,064 shares of the specialty pharmaceutical company's stock worth $483,000 after buying an additional 14,279 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in shares of Supernus Pharmaceuticals by 6.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 42,449 shares of the specialty pharmaceutical company's stock valued at $1,136,000 after purchasing an additional 2,605 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock worth $741,000 after purchasing an additional 600 shares during the period. Bank of New York Mellon Corp lifted its holdings in Supernus Pharmaceuticals by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company's stock worth $11,379,000 after purchasing an additional 2,427 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Supernus Pharmaceuticals by 20.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,083 shares of the specialty pharmaceutical company's stock valued at $350,000 after purchasing an additional 2,225 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.